HCP Perceptions on Oncology Management and Recent Advancements in India

Overview

The oncology landscape is undergoing a significant transformation, driven by Precision Oncology, Immunotherapy, Targeted Cancer Therapies, Molecular Profiling in Oncology, Liquid Biopsy, CAR-T Cell Therapy, Antibody-Drug Conjugates, and AI in Oncology.

This Oncology HCP Survey India examines HCP perceptions on oncology treatment and management, focusing on how healthcare professionals view recent Oncology Treatment Advancements, emerging technologies, treatment gaps, implementation barriers and the future of oncology treatment.

The findings provide HCP Oncology Insights into healthcare professional oncology perceptions and the evolving role of Personalized Cancer Treatment and Biomarker-Driven Treatment in clinical practice.

Survey Results Summary

Detailed Response Distribution

Q1. Importance of Continued Innovation

• Very High: 60%
• High: 36%
• Moderate: 4%
• Low: 0%
• Very High / High: 96%

The results indicate a strong perceived need for continued Oncology Treatment Advancements. For HCPs, ongoing innovation remains important as treatment gaps persist across different cancer types and patient populations.

Q2. Adequacy of Current Treatment Options

• Fully adequate: 12%
• Partially adequate: 76%
• Inadequate: 12%

The finding that 76% considered current treatment options partially adequate highlights continued unmet needs in oncology. This creates an opportunity for Emerging Oncology Therapies, including biomarker-driven approaches, novel targeted treatments and next-generation therapeutic platforms.

Q3. Most Important Advancement Over the Past 5 Years

• Immunotherapy and targeted therapies: 40%
• Antibody-drug conjugates (ADCs): 20%
• Precision oncology/biomarker-driven treatment: 16%
• CAR-T and other cellular therapies: 8%
• Liquid biopsy and molecular diagnostics: 8%
• Digital health/AI: 8%

The results highlight the breadth of recent oncology treatment advancements in India. Immunotherapy and Targeted Cancer Therapies were the most frequently selected category, followed by Antibody-Drug Conjugates and Precision Oncology.

The findings also demonstrate that HCPs recognize innovation across multiple dimensions—from therapies themselves to diagnostics and digital technologies.

Q4. Importance of Biomarkers, Molecular Profiling & Personalized Medicine

• Extremely important: 56%
• Very important: 36%
• Moderately important: 8%
• Low: 0%
• Extremely / Very important: 92%

This represents one of the strongest findings from the Oncology HCP Survey.

A combined 92% of respondents considered biomarkers, molecular profiling and personalized medicine extremely or very important. This supports the growing clinical relevance of Molecular Profiling in Oncology, Biomarker-Driven Treatment, and Personalized Cancer Treatment.

The finding also provides an important indicator of HCP views on precision oncology: treatment decisions are increasingly connected to the molecular characteristics of individual tumors and patient populations.

Q5. Expected Expansion of Adoption

• Yes: 88%
• Unsure: 8%
• No: 4%

A large majority of surveyed HCPs expect adoption of novel therapies, precision diagnostics and AI/digital health to expand.

This expectation reflects broader oncology treatment trends in India, where advances in molecular diagnostics, targeted therapies, cellular therapy and digital technologies are creating new possibilities for diagnosis and treatment planning.

Q6. Greatest Implementation Barriers

• Cost/access and late diagnosis: 56%
• Insurance/reimbursement and prior authorization: 16%
• Limited availability/validation of biomarkers and molecular testing: 12%
• Infrastructure, workforce and treatment capacity: 16%

The findings demonstrate that innovation and access cannot be considered separately.

For emerging therapies and technologies to achieve broader adoption, healthcare systems need adequate diagnostic capacity, trained oncology professionals, reimbursement mechanisms, treatment infrastructure and timely diagnosis.

These findings highlight the barriers to oncology treatment adoption, challenges in oncology treatment access, and broader oncology implementation challenges in India.

Q7. Expected Impact of Digital Health & AI

• Very likely: 48%
• Likely: 32%
• Neutral: 12%
• Unlikely: 8%
• Likely / Very likely: 80%

AI in Oncology is becoming an increasingly important component of the future oncology ecosystem.

Potential applications include clinical decision support, medical imaging, pathology, patient risk stratification, molecular data interpretation, clinical-trial matching, drug discovery and patient monitoring.

The 80% combined response indicates positive HCP views on AI in oncology, although expectations should be distinguished from demonstrated clinical outcomes.

The survey therefore provides a useful starting point for examining AI and digital health in oncology, particularly where AI can complement—not replace—clinical expertise.

Q8. Outlook for Oncology Over the Next Decade

• Very optimistic: 44%
• Optimistic: 48%
• Neutral: 4%
• Pessimistic: 4%
• Optimistic / Very optimistic: 92%

The results demonstrate a broadly positive outlook for the future of oncology treatment.

HCP expectations span continued development of Precision Oncology, Immunotherapy, Targeted Cancer Therapies, Antibody-Drug Conjugates, CAR-T Cell Therapy, Liquid Biopsy, molecular diagnostics and AI-enabled healthcare.

Key HCP Oncology Insights

The survey highlights several important themes in healthcare professional oncology perceptions.

1. Precision Oncology is becoming central to treatment strategy

The 92% importance rating for biomarkers, molecular profiling and personalized medicine demonstrates strong HCP recognition of precision approaches.

HCP perceptions of personalized medicine in oncology increasingly center on selecting therapies according to disease biology rather than relying exclusively on conventional tumor classifications.

2. Immunotherapy and targeted therapies remain prominent

At 40%, Immunotherapy and targeted therapies represented the most frequently selected recent advancement.

This indicates strong HCP perceptions of immunotherapy and HCP perceptions of targeted therapies within the surveyed population.

3. Emerging therapeutic platforms are broadening the oncology landscape

ADCs and CAR-T were recognized alongside conventional systemic approaches.

The survey therefore provides useful HCP perceptions of antibody-drug conjugates and HCP perceptions of CAR-T cell therapy, although the sample should not be interpreted as representative of all Indian HCPs.

4. Liquid biopsy has emerging relevance

Liquid biopsy and molecular diagnostics accounted for 8% of responses regarding the most important recent advancement.

The finding provides an initial indication of HCP perceptions of liquid biopsy and its potential role within precision diagnostics.

5. Access remains a major constraint

Despite optimism around innovation, cost, access and late diagnosis were identified as the leading combined implementation barrier.

This creates an important distinction between technology availability and technology accessibility.

Strategic Implications for Oncology Stakeholders

For pharmaceutical and biotechnology companies, these findings indicate the importance of connecting therapeutic innovation with biomarker strategy, patient identification and market access.

For healthcare providers, implementation of Emerging Oncology Therapies will depend on diagnostic infrastructure, workforce capabilities, multidisciplinary care and appropriate treatment capacity.

For oncology technology and healthcare SaaS companies, the opportunity lies in integrating fragmented information across clinical trials, biomarkers, therapies, KOLs and competitive intelligence.

For researchers and market intelligence teams, the survey provides a useful framework for monitoring oncology treatment trends, emerging technologies and evolving HCP expectations.

Overall HCP Takeaway

Among the 25 HCPs surveyed in India, 96% rated continued innovation as highly or very highly important, while 76% viewed current treatment options as partially adequate.

Immunotherapy and targeted therapies were the most frequently selected combined category for recent advances (40%). Biomarkers and personalized medicine were rated extremely or very important by 92% of respondents.

Although 88% expected adoption of new therapies, precision diagnostics and AI/digital health to expand, cost/access and late diagnosis remained the leading combined barriers at 56%.

Overall, 92% expressed an optimistic or very optimistic outlook for oncology over the next decade.

Taken together, these HCP Oncology Insights suggest that the next phase of oncology innovation will increasingly connect Precision Oncology, biomarker-driven treatment, novel therapeutic platforms and AI-enabled healthcare with the practical requirements of affordability, diagnosis and access.

Methodology & Interpretation

This was an exploratory survey of 25 HCPs in India. Each respondent represents 4 percentage points.

The results reflect this sample only and are not nationally representative. Perceptions and expectations should not be interpreted as actual adoption rates or clinical outcomes.

Q3 categories overlap conceptually, while Q5 combines multiple technology areas. All percentages should be validated against respondent-level data before publication.

Frequently Asked Questions

What are HCP perceptions on oncology treatment in India?

Among the surveyed HCPs, there was strong support for continued innovation, with 96% rating it highly or very highly important. However, 76% viewed current treatment options as only partially adequate.

What oncology treatment trends are emerging in India?

The survey highlights Immunotherapy, Targeted Cancer Therapies, Precision Oncology, Antibody-Drug Conjugates, CAR-T Cell Therapy, Liquid Biopsy and AI in Oncology as important areas of recent and expected development.

How important is Precision Oncology to HCPs?

In this survey, 92% rated biomarkers, molecular profiling and personalized medicine extremely or very important, indicating strong HCP views on precision oncology.

What are HCP perceptions of immunotherapy?

Immunotherapy and targeted therapies were the most frequently selected category for the greatest oncology advancement over the previous five years, accounting for 40% of responses.

What are the barriers to oncology treatment adoption?

Cost/access and late diagnosis were the leading combined barrier at 56%, followed by reimbursement/prior authorization, infrastructure/workforce limitations and biomarker availability or validation.

What is the role of AI and digital health in oncology?

AI and digital health may support applications including imaging, pathology, molecular data analysis, clinical decision support, clinical-trial matching and patient monitoring. In this survey, 80% considered their potential impact likely or very likely to improve outcomes.

What is the future of oncology treatment?

The surveyed HCPs expressed a broadly positive outlook, with 92% describing their outlook for oncology over the next decade as optimistic or very optimistic.

Conclusion

The Oncology HCP Survey India provides a snapshot of how healthcare professionals perceive the rapidly changing oncology landscape.

The strongest signal is the growing importance of Precision Oncology, supported by high ratings for biomarkers, Molecular Profiling in Oncology and Personalized Cancer Treatment.

At the same time, HCP perceptions extend across Immunotherapy, Targeted Cancer Therapies, Antibody-Drug Conjugates, CAR-T Cell Therapy, Liquid Biopsy and AI in Oncology.

The central challenge is translating these Oncology Treatment Advancements into accessible clinical care. Cost, late diagnosis, reimbursement, diagnostic availability, infrastructure and workforce capacity remain important considerations.

For oncology stakeholders, the opportunity is therefore not simply to develop new therapies, but to build an ecosystem where biomarker-driven treatment, emerging oncology therapies and technology-enabled care can be effectively connected to evidence, clinical workflows and patient access.